Litigation Details for Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)
✉ Email this page to a colleague
Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-02-14 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
Jury Demand | None | Referred To | |
Patents | 6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; RE41,783 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Pfizer Inc. v. Micro Labs USA Inc.
Biologic Drugs cited in Pfizer Inc. v. Micro Labs USA Inc.
Details for Pfizer Inc. v. Micro Labs USA Inc. (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-02-14 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2; 7,301,023 B2; RE41,783…14 February 2017 1:17-cv-00158-LPS Patent None District Court, D. Delaware | External link to document | |
2018-06-27 | 78 | Complaint - Amended | four additional patents for Xeljanz® that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…of United States Patent No. 6,965,027 (the “’027 patent”) and United States Patent No. 7,301,023 (the…expiration date for the ’027 patent as March 25, 2023 and the ’023 patent as May 23, 2022. 24…expiration date of the RE’783 patent to December 8, 2025. The ’027 Patent 25. On November ….” The ’027 patent is duly and legally assigned to Pfizer Inc. A copy of the ’027 patent is attached | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |